AdAlta Limited, a drug discovery and development company, develops protein therapeutics. The company focuses on developing its lead i-body drug candidate, AD-114, for the treatment of idiopathic pulmonary fibrosis and other fibrotic diseases. It has a collaborative partnership with Excellerate Bioscience to advance the development of its i-body pipeline. AdAlta Limited was incorporated in 2006 and is based in Bundoora, Australia.